NCT04933604

Brief Summary

The study aims to investigate the rationale for LPN in patients with high-complexity renal tumors in terms of oncologic and functional outcomes.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
78

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Sep 2019

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2019

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 30, 2020

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 4, 2021

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

May 31, 2021

Completed
22 days until next milestone

First Posted

Study publicly available on registry

June 22, 2021

Completed
Last Updated

June 22, 2021

Status Verified

June 1, 2021

Enrollment Period

9 months

First QC Date

May 31, 2021

Last Update Submit

June 13, 2021

Conditions

Keywords

Laparoscopynephrometry scorepartial nephrectomypropensity score matchingradical nephrectomy

Outcome Measures

Primary Outcomes (8)

  • Operation time

    time from onset to complete of surgery

    at the end of the surgery

  • Blood loss

    amount of bleeding during surgery (mL)

    at the end of the surgery

  • warm ischemia time

    The clamp time of the renal artery and vein which is required to complete tumor excision and renorrhaphy

    at the and of the surgery

  • Postoperative complication

    abnormal problmes that may be seen after surgery and require additional intervention, treatment or follow-up

    up to 3 months postoperatively

  • functional outcomes

    serum creatinine level (mg /dL) and estimated glomerular filtration rate (CKD Epidemiology Collaboration (CKD-EPI) equation) (mL/min/1.73 m2)

    1 year after the surgery

  • surigcal margin status

    presence or absence of tumors at the surgical margin

    postoperative follow-up, through study completion, an average of 1 year

  • CKD stage upgrading

    evaluation of preoperative and postoperative renal functions according to chronic kidney disease stages

    postoperative follow-up, through study completion, an average of 1 year

  • Oncological outomes

    Presence or absence of local and/or distal tumor recurrence

    postoperative follow-up, through study completion, an average of 1 year

Study Arms (2)

LPN group

39 patients with high complexity renal tumors who underwent laparoscopic partial nephrectomy

Procedure: laparoscopic partial nephrectomy

LRN group

39 patients with high complexity renal tumors who underwent laparoscopic radical nephrectomy

Procedure: Laparoscopic radical nephrectomy

Interventions

Nephron sparing minimally invasive surgery

LPN group

Completely removal of kidney by using laparoscopic surgery

LRN group

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

From November 2009 to October 2018, 399 patients underwent LPN and 307 patients to laparoscopic radical nephrectomy (LRN). 41 patients with RENAL score ≥ 10 enrolled in LPN and 265 patients to the LRN group. Propensity score matching (matched by age, gender, clinical tumor stage, tumor size, baseline renal function, comorbidities such as diabetes mellitus (DM), hypertension (HT), coronary artery disease (CAD) and final tumor pathology of RCC) was used to reduce selection bias. Functional and oncological outcomes were compared between the two groups. After propensity score analysis, 39 patients in the LRN group were matched with 39 in the LPN group.

You may qualify if:

  • Patients with complete data
  • Patients with single renal tumor on the effected side
  • Patients who approved the written consent form

You may not qualify if:

  • Patients who not approved the written consent form
  • Patients with incomplete data
  • Patients with low or mild complexity renal tumors

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ondokuz Mayıs University, Department of Urology

Samsun, 55020, Turkey (Türkiye)

Location

Related Publications (3)

  • Kim SP, Campbell SC, Gill I, Lane BR, Van Poppel H, Smaldone MC, Volpe A, Kutikov A. Collaborative Review of Risk Benefit Trade-offs Between Partial and Radical Nephrectomy in the Management of Anatomically Complex Renal Masses. Eur Urol. 2017 Jul;72(1):64-75. doi: 10.1016/j.eururo.2016.11.038. Epub 2016 Dec 14.

  • Mir MC, Derweesh I, Porpiglia F, Zargar H, Mottrie A, Autorino R. Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies. Eur Urol. 2017 Apr;71(4):606-617. doi: 10.1016/j.eururo.2016.08.060. Epub 2016 Sep 7.

  • Yang F, Zhou Q, Xing N. Comparison of survival and renal function between partial and radical laparoscopic nephrectomy for T1b renal cell carcinoma. J Cancer Res Clin Oncol. 2020 Jan;146(1):261-272. doi: 10.1007/s00432-019-03058-z. Epub 2019 Nov 1.

MeSH Terms

Conditions

Kidney NeoplasmsCarcinoma, Renal CellNeoplasmsUrologic Neoplasms

Condition Hierarchy (Ancestors)

Urogenital NeoplasmsNeoplasms by SiteFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesKidney DiseasesUrologic DiseasesMale Urogenital DiseasesAdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic Type

Study Officials

  • Ender Ozden, Prof.

    Ondokuz Mayıs Üniversitesi, Tıp Fakültesi, Üroloji Anabilim dalı

    STUDY DIRECTOR
  • Saban Sarıkaya, Prof.

    Ondokuz Mayıs University, Faculty of Medicine, Department of Urology

    STUDY CHAIR
  • Mehmet Mercimek, MD, FEBU

    Liv Hospital Samsun, Department of Urology

    PRINCIPAL INVESTIGATOR
  • Yakup Bostancı, Prof.

    Ondokuz Mayıs University, Faculty of Medicine, Department of Urology

    PRINCIPAL INVESTIGATOR
  • Murat Gulsen, MD

    Samsun Gazi State Hospital, Departmen of Urology, Samsun, Turkey

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

May 31, 2021

First Posted

June 22, 2021

Study Start

September 1, 2019

Primary Completion

May 30, 2020

Study Completion

February 4, 2021

Last Updated

June 22, 2021

Record last verified: 2021-06

Locations